These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Paisley AN; Roberts ME; Trainer PJ Clin Endocrinol (Oxf); 2007 May; 66(5):723-6. PubMed ID: 17388793 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. Chieffo C; Cook D; Xiang Q; Frohman LA J Clin Endocrinol Metab; 2013 Oct; 98(10):4047-54. PubMed ID: 23969184 [TBL] [Abstract][Full Text] [Related]
44. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly. Stolk MF; van Erpecum KJ; Koppeschaar HP; de Bruin WI; Jansen JB; Lamers CB; van Berge Henegouwen GP Gut; 1993 Jun; 34(6):808-13. PubMed ID: 8314514 [TBL] [Abstract][Full Text] [Related]
45. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. Ho PJ; Boyajy LD; Greenstein E; Barkan AL Dig Dis Sci; 1993 Feb; 38(2):309-15. PubMed ID: 8425442 [TBL] [Abstract][Full Text] [Related]
46. Effect of short-term octreotide therapy and total parenteral nutrition on the development of biliary sludge and lithiasis. Baudet S; Medina C; Vilaseca J; Guarner L; Sureda D; Andreu J; Malagelada JR Hepatogastroenterology; 2002; 49(45):609-12. PubMed ID: 12063951 [TBL] [Abstract][Full Text] [Related]
47. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion. Moller DE; Moses AC; Jones K; Thorner MO; Vance ML J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033 [TBL] [Abstract][Full Text] [Related]
48. Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly. Atmaca A; Erbas T Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):340-3. PubMed ID: 15977102 [TBL] [Abstract][Full Text] [Related]
49. Gallstone disease: Microlithiasis and sludge. Jüngst C; Kullak-Ublick GA; Jüngst D Best Pract Res Clin Gastroenterol; 2006; 20(6):1053-62. PubMed ID: 17127187 [TBL] [Abstract][Full Text] [Related]
50. Histopathological improvement of acromegalic cardiomyopathy by intermittent subcutaneous infusion of octreotide. Nishiki M; Murakami Y; Sohmiya M; Koshimura K; Inoue K; Goto Y; Nakamura N; Kato Y Endocr J; 1997 Oct; 44(5):655-60. PubMed ID: 9466320 [TBL] [Abstract][Full Text] [Related]
51. Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up. Schmidt K; Althoff PH; Harris AG; Prestele H; Schumm-Draeger PM; Usadel KH Pain; 1993 May; 53(2):223-227. PubMed ID: 8336992 [TBL] [Abstract][Full Text] [Related]
52. Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report. Sheehan MT; Nippoldt TB Pituitary; 2000 Dec; 3(4):227-30. PubMed ID: 11788010 [TBL] [Abstract][Full Text] [Related]
53. Octreotide stimulates Ca++ secretion by the gallbladder: a risk factor for gallstones. Moser AJ; Giurgiu DI; Morgenstern KE; Abedin ZR; Roslyn JJ; Abedin MZ Surgery; 1999 May; 125(5):509-13. PubMed ID: 10330939 [TBL] [Abstract][Full Text] [Related]
54. Changes in glucose tolerance and development of gall stones during high dose treatment with octreotide for acromegaly. McKnight JA; McCance DR; Crothers JG; Atkinson AB BMJ; 1989 Sep; 299(6699):604-5. PubMed ID: 2508821 [No Abstract] [Full Text] [Related]
55. Octreotide is effective in acromegaly but often results in cholelithiasis. Daughaday WH Ann Intern Med; 1990 Feb; 112(3):159-60. PubMed ID: 2404444 [No Abstract] [Full Text] [Related]
56. Effects of long term octreotide on gall stone formation and gall bladder function. Bigg-Wither GW; Ho KK; Grunstein RR; Sullivan CE; Doust BD BMJ; 1992 Jun; 304(6842):1611-2. PubMed ID: 1628089 [No Abstract] [Full Text] [Related]
57. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis. Roti E; Minelli R; Gardini E; Salvi M; Bianconi L; Balducci L; Manfredi A; Braverman LE J Endocrinol Invest; 1990 Jan; 13(1):69-72. PubMed ID: 2319110 [TBL] [Abstract][Full Text] [Related]